Related content

miRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines

By Gu Jingyi  

Medical Oncology, Vol. 28, Iss. 1, 2011-03 ,pp. : 211-218

Humana Press, Inc

Access to resources Recommend Favorite

Arsenic Trioxide: Its Use in the Treatment of Acute Promyelocytic Leukemia

By Sanz Miguel A.  

American Journal of Cancer, Vol. 5, Iss. 3, 2006-01 ,pp. : 183-191

Adis International

Access to resources Recommend Favorite

hsa-miR-203 enhances the sensitivity of leukemia cells to arsenic trioxide

By              

Experimental and Therapeutic Medicine, Vol. 5, Iss. 5, 2013-01 ,pp. : 1315-1321

Spandidos Publications

Access to resources Recommend Favorite

Carcinogenic risk of retained arsenic after successful treatment of acute promyelocytic leukemia with arsenic trioxide: a cause for concern?

By Firkin Frank  

Leukemia and Lymphoma, Vol. 55, Iss. 5, 2014-05 ,pp. : 977-978

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide

By Fujisawa Shinya   Ohno Ryuzo   Shigeno Kazuyuki   Sahara Naohi   Nakamura Satoki   Naito Kensuke   Kobayashi Miki   Shinjo Kaori   Takeshita Akihiro   Suzuki Yoshinari   Hashimoto Hisakuni   Kinoshita Kenji   Shimoya Masahito   Kaise Toshikazu   Ohnishi Kazunori  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 4, 2007-03 ,pp. : 485-493

Springer Publishing Company

Access to resources Recommend Favorite